400 related articles for article (PubMed ID: 31454760)
1. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.
Vogrig A; Fouret M; Joubert B; Picard G; Rogemond V; Pinto AL; Muñiz-Castrillo S; Roger M; Raimbourg J; Dayen C; Grignou L; Pallix-Guyot M; Lannoy J; Ducray F; Desestret V; Psimaras D; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454760
[TBL] [Abstract][Full Text] [Related]
2. Central nervous system complications associated with immune checkpoint inhibitors.
Vogrig A; Muñiz-Castrillo S; Joubert B; Picard G; Rogemond V; Marchal C; Chiappa AM; Chanson E; Skowron F; Leblanc A; Ducray F; Honnorat J
J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):772-778. PubMed ID: 32312871
[TBL] [Abstract][Full Text] [Related]
3. Anti-Ma2/Ta paraneoplastic rhombencephalitis in a patient with lung cancer responsive to anti-PD1 therapy.
Leempoel J; Ruyssen A; Kessler R; Van Pesch V; Gille M
Acta Neurol Belg; 2020 Apr; 120(2):451-452. PubMed ID: 31264180
[No Abstract] [Full Text] [Related]
4. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes.
Gill A; Perez MA; Perrone CM; Bae CJ; Pruitt AA; Lancaster E
J Neuroimmunol; 2019 Sep; 334():576980. PubMed ID: 31195181
[TBL] [Abstract][Full Text] [Related]
5. [Anti-Ma2-associated encephalitis and paraneoplastic limbic encephalitis].
Yamamoto T; Tsuji S
Brain Nerve; 2010 Aug; 62(8):838-51. PubMed ID: 20714032
[TBL] [Abstract][Full Text] [Related]
6. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
7. Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome.
Vogrig A; Joubert B; Maureille A; Thomas L; Bernard E; Streichenberger N; Cotton F; Ducray F; Honnorat J
J Neurol; 2019 Feb; 266(2):398-410. PubMed ID: 30498914
[TBL] [Abstract][Full Text] [Related]
8. Clinical analysis of anti-Ma2-associated encephalitis.
Dalmau J; Graus F; Villarejo A; Posner JB; Blumenthal D; Thiessen B; Saiz A; Meneses P; Rosenfeld MR
Brain; 2004 Aug; 127(Pt 8):1831-44. PubMed ID: 15215214
[TBL] [Abstract][Full Text] [Related]
9. Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: Case report and review of literature.
Raibagkar P; Ho D; Gunturu KS; Srinivasan J
J Neuroimmunol; 2020 Apr; 341():577184. PubMed ID: 32058173
[TBL] [Abstract][Full Text] [Related]
10. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database.
Garon-Czmil J; Petitpain N; Rouby F; Sassier M; Babai S; Yelehe-Okouma M; Weryha G; Klein M; Gillet P
Fundam Clin Pharmacol; 2019 Apr; 33(2):241-249. PubMed ID: 30308083
[TBL] [Abstract][Full Text] [Related]
11. Neurotoxicities associated with immune checkpoint inhibitor therapy.
Duong SL; Barbiero FJ; Nowak RJ; Baehring JM
J Neurooncol; 2021 Apr; 152(2):265-277. PubMed ID: 33454891
[TBL] [Abstract][Full Text] [Related]
12. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Kitagataya T; Suda G; Nagashima K; Katsurada T; Yamamoto K; Kimura M; Maehara O; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Komatsu Y; Hata H; Takeuchi S; Abe T; Sakakibara-Konishi J; Teshima T; Homma A; Sakamoto N
J Gastroenterol Hepatol; 2020 Oct; 35(10):1782-1788. PubMed ID: 32187734
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis outcomes after cancer immunotherapy.
Garcia CR; Jayswal R; Adams V; Anthony LB; Villano JL
Clin Transl Oncol; 2019 Oct; 21(10):1336-1342. PubMed ID: 30788836
[TBL] [Abstract][Full Text] [Related]
14. Anti-Ma2-Associated Limbic Encephalitis after Termination of Immune Checkpoint Inhibitor Therapy for Malignant Pleural Mesothelioma.
Hashimoto R; Tanabe E; Otsuka Y; Yoneda Y; Kageyama Y
Case Rep Neurol; 2021; 13(3):724-728. PubMed ID: 34950011
[TBL] [Abstract][Full Text] [Related]
15. Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study.
Babai S; Voisin AL; Bertin C; Gouverneur A; Le-Louet H
Drug Saf; 2020 Feb; 43(2):111-117. PubMed ID: 31630381
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
[TBL] [Abstract][Full Text] [Related]
17. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
[TBL] [Abstract][Full Text] [Related]
18. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
[TBL] [Abstract][Full Text] [Related]
20. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
